Literature DB >> 18311481

Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance.

Shunzo Kobayashi1.   

Abstract

Subtyping of breast cancers by means of DNA microarray analyses has given rise to the new concept of the basal-like subtype; this subtype is in effect the equivalent of so-called "triple-negative" breast cancer. Basal-like breast cancer has aggressive characteristics, such as high histological grade, mutation of the TP53 gene, and negative hormone receptors. It tends to occur in relatively young women and is highly correlated with suppression of BRCA1 function. The EGFR gene is often overexpressed in this subtype. Here, research carried out in the last few years into the basal-like subtype of breast cancer will be reviewed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18311481     DOI: 10.1007/s12282-008-0034-3

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  11 in total

1.  Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer.

Authors:  Jiannan Wu; Shunrong Li; Weijuan Jia; Fengxi Su
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-10       Impact factor: 4.553

2.  Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer.

Authors:  Keli Xu; Jerry Usary; Philaretos C Kousis; Aleix Prat; Dong-Yu Wang; Jessica R Adams; Wei Wang; Amanda J Loch; Tao Deng; Wei Zhao; Robert Darrell Cardiff; Keejung Yoon; Nicholas Gaiano; Vicki Ling; Joseph Beyene; Eldad Zacksenhaus; Tom Gridley; Wey L Leong; Cynthia J Guidos; Charles M Perou; Sean E Egan
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

3.  MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer.

Authors:  Dawn R Cochrane; Diana M Cittelly; Erin N Howe; Nicole S Spoelstra; Erin L McKinsey; Kelly LaPara; Anthony Elias; Douglas Yee; Jennifer K Richer
Journal:  Horm Cancer       Date:  2010-12       Impact factor: 3.869

Review 4.  The genesis and evolution of high-grade serous ovarian cancer.

Authors:  David D L Bowtell
Journal:  Nat Rev Cancer       Date:  2010-10-14       Impact factor: 60.716

5.  The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells.

Authors:  Brian D Adams; Danielle M Cowee; Bruce A White
Journal:  Mol Endocrinol       Date:  2009-05-07

6.  Skp2B overexpression alters a prohibitin-p53 axis and the transcription of PAPP-A, the protease of insulin-like growth factor binding protein 4.

Authors:  Harish Chander; Max Halpern; Lois Resnick-Silverman; James J Manfredi; Doris Germain
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

7.  Toca-1 is suppressed by p53 to limit breast cancer cell invasion and tumor metastasis.

Authors:  Harish Chander; Colin D Brien; Peter Truesdell; Kathleen Watt; Jalna Meens; Colleen Schick; Doris Germain; Andrew W B Craig
Journal:  Breast Cancer Res       Date:  2014-12-30       Impact factor: 6.466

8.  Immunoexpression of P63 and SOX2 in triple-negative breast cancers, Indonesia.

Authors:  Reno K Kamarlis; Muhammad Nd Lubis; Bethy S Hernowo; Azmi S Kar
Journal:  F1000Res       Date:  2017-09-28

9.  Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid.

Authors:  Toni Ibrahim; Laura Mercatali; Emanuele Sacanna; Anna Tesei; Silvia Carloni; Paola Ulivi; Chiara Liverani; Francesco Fabbri; Michele Zanoni; Wainer Zoli; Dino Amadori
Journal:  Cancer Cell Int       Date:  2012-11-22       Impact factor: 5.722

Review 10.  Targeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast Cancer.

Authors:  Kamila A Marzec; Robert C Baxter; Janet L Martin
Journal:  Biomed Res Int       Date:  2015-06-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.